SPLICE-REGION ANTISENSE COMPOSITION AND METHOD
First Claim
1. An antisense compound having an uncharged morpholino backbone and a base sequence between 12 and 25 nucleotide bases in length which is complementary to a target region of a selected preprocessed mRNA coding for a protein selected from the group consisting of myc, myb, ref fos, jun, abl, bcl, p53, an integrin, a cathedrin, a telomerase, a cytokine, a kinase, a receptor protein, hCG, HIV rev, human papilloma virus, and human parvovirus B19,where the 5′
- end of the target region is 1-25 bases downstream of a normal splice acceptor site in said preprocessed mRNA.
2 Assignments
0 Petitions
Accused Products
Abstract
Antisense compositions targeted against an mRNA sequence coding for a selected protein, at a region having its 5′ end from 1 to about 25 base pairs downstream of a normal splice acceptor junction in the preprocessed mRNA, are disclosed. The antisense compound is RNase-inactive, and is preferably a phosphorodiamidate-linked morpholino oligonucleotide. Such targeting is effective to inhibit natural mRNA splice processing, produce splice variant mRNAs, and inhibit normal expression of the protein.
-
Citations
30 Claims
-
1. An antisense compound having an uncharged morpholino backbone and a base sequence between 12 and 25 nucleotide bases in length which is complementary to a target region of a selected preprocessed mRNA coding for a protein selected from the group consisting of myc, myb, ref fos, jun, abl, bcl, p53, an integrin, a cathedrin, a telomerase, a cytokine, a kinase, a receptor protein, hCG, HIV rev, human papilloma virus, and human parvovirus B19,
where the 5′ - end of the target region is 1-25 bases downstream of a normal splice acceptor site in said preprocessed mRNA.
- View Dependent Claims (2, 3, 4, 5, 6, 7)
-
8-22. -22. (canceled)
-
23. A method of inhibiting normal splicing of mRNA in a eukaryotic cell, comprising contacting the cell with an antisense compound having an uncharged morpholino backbone and a base sequence between 12 and 25 nucleotide bases in length which is complementary to a target region of a selected preprocessed mRNA coding for a selected protein;
- where the 5′
end of the target region is 1-25 bases downstream of a normal splice acceptor site in said preprocessed mRNA,wherein the compound; is taken up by the cell; hybridizes to the target region of preprocessed mRNA in the cell, and being so hybridized, prevents splicing at said normal acceptor splice site, such that the splice mechanism proceeds to a downstream splice acceptor sequence in the mRNA, producing a splice variant processed mRNA with a truncated coding sequence. - View Dependent Claims (24, 25, 26, 27, 28, 29)
- where the 5′
-
30-38. -38. (canceled)
Specification